Lupin may head higher, says Tushar Mahajan

Tushar Mahajan - head of listed futures & options for India at Nomura Financial Advisory told CNBC-TV18, "We saw some sharp moves in Lupin and Sun Pharma just from a trading point of view last week itself. However, overall we like Lupin, we think this could continue to trade higher but from a short-term perspective I don’t think there is too much upside on Lupin or Sun Pharma."

At 11:48 hrs Lupin was quoting at Rs 1,988.80, up Rs 8, or 0.40 percent. It has touched an intraday high of Rs 2,000 and an intraday low of Rs 1,975.